• Non-statin drugs do not have a large volume of data from randomized clinical trials (RCTs) to guide therapy but reasonable evidence exists for the fibrates, gemfibrozil, nicotinic acid, and the resins.
• Non-statin drugs may be indicated in patients intolerant of statins or in whom statins are contraindicated.
• Non-statin drugs may be added to statin therapy to obtain further effects on low-density lipoprotein (LDL) if treatment goals are not achieved on maximum-tolerated statin dose.
• Non-statin drugs may be added to statin therapy to obtain further effects in increasing high-density lipoprotein (HDL) and reducing triglyceride.
In the last 10 years the understanding of hyperlipidaemia has advanced greatly. This resource provides a practical approach to therapy, addresses common clinical problems and looks to the future of treatment for the condition, focusing on new therapeutic targets. In essence it translates clinical trial science into everyday clinical practice.
Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up to date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this work.
